The Oxford Vaccine could make a critical contribution to the COVID-19 campaign. This is because is far cheaper and easier to store than other available alternatives. And moreover reach remote parts of the world, because it stores at standard fridge temperature. However, recent reports on the trial suggest it may be only 70% effective. But we have dug deeper to discover the facts and potential of the Oxford Vaccine.
Unpicking the Facts and True Potential of the Oxford Vaccine
Wall Street Journal confirmed a statement by AstraZeneca PLC and University of Oxford. They said ‘Their Covid-19 vaccine was as much as 90% effective in preventing infections without serious side effects in large clinical trials. However, its efficacy varied depending on dose size. This boosts hopes of a third Western vaccine becoming available by the end of 2020.
The trial confirmed an overall efficacy of an average 70.4%, according to The Independent news channel. But this increased to around 90% where patients received a half dose of the vaccine first time. And a full dose followed a month later, according to the vaccine group’s director Professor Andrew Pollard.
More Interesting Snippets About the Oxford Vaccine
There were no severe cases, and no hospitalizations among thousands of people in the trial. The facts and potential of the Oxford Vaccine thus include preventing the disease at low risk, and avoiding any subsequent hospitalizations.
The UK government has ordered 100 million doses. But the timing means the bulk of rollout will be in January, February, and March 2021. Secretary of State for Health and Social Care, Matt Hancock was warmly positive. When he said, ‘we hope that sometime after Easter things will be able to start to get back to normal.’
Related
Broad Immune Response to Oxford Vaccine
Oxford Vaccine Makes Antibodies and T-Cells
Preview Image: Dose of Oxford Vaccine
Oxford University Press Release
Video Share Link: https://youtu.be/xHJ_RqeXXy0
